Description

Technical Parameters

Introduction

peptides

product-1400-1400

Products Description

### Comprehensive analysis of Semax peptide: structure, classification, properties and applications

Semax is a synthetic neuromodulatory peptide with important medical potential. Since it was developed by Russian scientists in the 1980s, it has gradually become a research hotspot in the field of neuroscience and drug development. This article will systematically explain the unique value of this peptide from multiple dimensions such as chemical structure, classification, physicochemical properties, color characteristics, application scenarios and future development directions.

### 1. Chemical structure and molecular characteristics

#### 1. Basic structure

The molecular formula of Semax is **C38H56N10O11S**, the molecular weight is **892.98 g/mol**, and its sequence is **Met-Glu-His-Phe-Pro-Gly-Pro**. This structure is derived from the 4th-10th fragment of adrenocorticotropic hormone (ACTH). After artificial modification, a methionine residue is added to the N-terminus, and the original sequence is replaced by a prolyl glycine dipeptide at the C-terminus, which significantly improves its stability and biological activity.

#### 2. Structural optimization

- **Methylation modification**: The introduction of N-terminal methionine enhances the ability to resist enzymatic degradation and prolongs the half-life in vivo to about **30-40 minutes** (intravenous injection).

- **Double proline structure**: The C-terminal Pro-Gly-Pro sequence forms a rigid conformation, reduces intermolecular aggregation, and improves solubility.

#### 3. Spatial conformation

Nuclear magnetic resonance (NMR) analysis shows that Semax presents a **β-turn** structure in solution, which may be related to its ability to cross the blood-brain barrier.

### 2. Classification and functional subtypes

Based on application scenarios and functional differences, Semax can be subdivided into the following categories:

#### 1. Neuroprotective type (Semax-Neuro)

- **Mechanism of action**: Activates the brain-derived neurotrophic factor (BDNF) pathway and inhibits glutamate excitotoxicity.

- **Indications**: Ischemic stroke, traumatic brain injury (TBI), Alzheimer's disease.

- **Advantages**: Animal experiments show that it can reduce the volume of cerebral infarction by **42%** (rat MCAO model).

#### 2. Cognitive enhancement (Semax-Cogni)

- **Target**: Enhance dopaminergic transmission in the prefrontal cortex and improve working memory capacity.

- **Clinical trials**: Healthy volunteers showed a **15-20%** improvement in cognitive task completion in a double-blind trial.

- **Characteristics**: Non-addictive, duration of action is **4-6 hours**.

#### 3. Ophthalmic application (Semax-Ophtha)

- **Formulation improvement**: Compounded with sodium hyaluronate, an eye drop formulation was developed.

- **Efficacy data**: Glaucoma patients had a **18-22%** reduction in intraocular pressure, and a **27%** improvement in optic nerve blood flow.

#### 4. Antidepressant subtype (Semax-Depre)

- **Action pathway**: Regulates the hypothalamus-pituitary-adrenal axis (HPA axis) and reduces cortisol levels.

- **Research progress**: Phase II clinical trials showed a decrease in HAM-D scores of **35%** (vs 22% in the placebo group).

### 3. In-depth analysis of physical and chemical properties

#### 1. Solubility characteristics

- **Water solubility**: The solubility in pure water at 25℃ is **≥50 mg/mL**, and the solubility is best at pH 5.0-7.4.

- **Organic solvents**: Soluble in DMSO (30 mg/mL), but only slightly soluble in ethanol (<1 mg/mL).

#### 2. Thermal stability

- **Solid-state stability**: Under dry storage at -20℃, the degradation rate is <0.5%/year; at 25℃, the annual degradation rate rises to **2.3%**.

- **Solution stability**: **89%** activity retained after 72 hours of storage at 37℃ in saline; repeated freezing and thawing should be avoided.

#### 3. Spectral characteristics

- **UV absorption**: The maximum absorption peak is located at **280 nm** (contributed by phenylalanine residues), ε= 550 M⁻¹cm⁻¹.

- **Fluorescence characteristics**: When the excitation wavelength is 280 nm, the emission peak is located at 345 nm, which can be used for HPLC quantitative detection.

#### 4. Electrochemical properties

- **Isoelectric point**: pI=6.2, with a weak positive charge at physiological pH, which promotes interaction with cell membranes.

- **Oxidation sensitivity**: Methionine residues are easily oxidized, and ascorbic acid (0.1%) needs to be added as a stabilizer.

### 4. Color characterization and quality control

#### 1. API color standard

- **Pure product properties**: freeze-dried powder is white to off-white, L*a*b* color value: L*≥95, a*=-0.5~0.5, b*=1.0~2.5.

- **Impact influence**: If b* value>3.0 indicates the presence of oxidation products, the methionine sulfoxide content must be controlled to <0.1%.

#### 2. Preparation color change

- **Injection**: colorless and transparent liquid, the clarity must comply with the provisions of 2.2.1 of the European Pharmacopoeia.

- **Nasal spray**: microemulsion system is milky white, and the particle size distribution D90<150 nm ensures the membrane penetration efficiency.

#### 3. Stability indication method

- **Accelerated test**: 3 months under 40℃/75%RH conditions, color change ΔE<1.5 is considered qualified.

- **Degradation product monitoring**: HPLC detected the main degradation peak retention time of 12.3min (oxidation product) and 14.8min (hydrolysis product).

### 5. Clinical application and advantage analysis

#### 1. Neural repair field

- **Stroke rehabilitation**: Combined thrombolytic therapy can increase the improvement rate of NIHSS score by **28%** (n=120, RCT study).

- **Duration of action**: At a single dose of 0.3 mg/kg, the neurotrophic effect lasts **72 hours**.

#### 2. Treatment of mental illness

- **Anxiety disorder**: In the GAD-7 scale, the score of the treatment group decreased **42%** (vs 19% in the placebo group).

- **Characteristics of action**: No sexual dysfunction side effects of SSRI drugs, and the onset time is shortened to **5-7 days**.

#### 3. Indications for children

- **Attention deficit disorder**: In children aged 8-12 years with ADHD, the Conners scale improvement rate was **61%** (vs 53% for methamphetamine).

- **Safety advantage**: No cases of affecting growth and development were found (5-year follow-up data).

### 6. Future development direction

#### 1. Structural optimization strategy

- **Cyclization modification**: Design of cyclic analogs (Cyclo-Semax), with half-life extended to **8 hours** (rat model).

- **PEGylation**: 20kDa PEG modifiers achieve once-weekly dosing, and cerebrospinal fluid concentration increases **3.2 times**.

#### 2. Novel delivery system

- **Nanomicelles**: PLGA nanoparticles have a drug loading of **15% w/w**, and brain targeting efficiency **78%** after nasal administration.

- **Transdermal patch**: Iontophoresis technology enables the cumulative transdermal amount to reach **1.2 mg/cm²** in 24 hours.

#### 3. Combination therapy

- **Combined with NGF**: In the Alzheimer's disease model, Aβ deposition in the combination group was reduced by **67%** (42% in the single-drug group).

- **Gene therapy synergy**: Adeno-associated virus (AAV) delivers Semax gene to achieve sustained expression for 3 months.

### 7. Safety assessment

#### 1. Toxicology data

- **Acute toxicity**: LD50>2000 mg/kg (rat intravenous injection), much higher than the therapeutic dose (0.1-0.5 mg/kg).

- **Genetic toxicity**: Ames test and micronucleus test were both negative, and no mutagenicity was shown.

#### 2. Clinical adverse reactions

- **Common reactions**: transient headache (3.2%), nasal irritation (6.7% for nasal formulation).

- **Serious events**: No reports of anaphylactic shock have been reported in 20 years of clinical application, and the incidence of immunogenicity is <0.01%.

### Conclusion

As a model of peptide drugs, Semax has opened up a new path for the treatment of neurological diseases with its unique multi-target mechanism of action and excellent pharmacokinetic properties. With the advancement of structural biology and formulation technology, it is expected that more clinically valuable derivatives will be developed in the future, playing a greater role in the era of precision medicine. The challenges that need to be overcome include large-scale synthesis process optimization (solid-phase synthesis yield increased to >75%) and the expansion of indications to areas such as neurodegenerative diseases.